Tumor biopsy is currently the gold standard for diagnosis and in determining cell signaling pathways involved in the development of treatment resistance. However, there are major challenges with this technique, including the need for serial sampling to monitor treatment resistance, which is invasive and also has the potential for selection bias due to intra-tumoral and inter-tumoral heterogeneity. These challenges highlight the need for more effective methods for obtaining Tumor samples. Liquid biopsy analyzes genetic material or tumor cells shed into the blood from the primary tumor and metastatic sites and consequently provides a comprehensive, real-time picture of the tumor burden in an individual patient. Indeed, liquid biopsy has the potential to revolutionize cancer management. Here, we review recent studies on the potential clinical applications of liquid biopsy using circulating tumor DNA in colorectal cancer, including screening, diagnosis, detection of minimal residual disease after surgery, detection of recurrence, prognosis, predicting treatment response, monitoring tumor burden or response during treatment, and tracking resistance. We also discuss recent data demonstrating the utility of detecting KRAS-mutated circulating tumor DNA, both at diagnosis to determine an appropriate treatment strategy and during anti-epidermal growth factor receptor therapy to predict treatment resistance. The future integration of liquid biopsy into clinical practice is discussed, together with alternative approaches and key questions that need to be answered in future clinical studies before this technology can be implemented and used routinely.
Introduction
The clinical outcome of patients with cancer is mainly determined by the blood-borne dissemination of cancer cells from the primary site to distant organs and the eventual outgrowth of a largely unknown subset of these cells into metastases in their new microenvironment. 1 Almost all cancers treated with tumor-specific therapies acquire resistance due to tumor heterogeneity, clonal evolution, and selection. 2 Subclones may also arise during disease progression, leading to changes in the proportion and pattern of specific aberrations among the tumor cells composing the primary tumor as well as the tumor cells of the metastatic lesions. 3, 4 Since therapy-related biomarkers may change throughout tumor progression, serial biomarker investigations may provide crucial information for therapy selection and, thus, personalized treatment. 5 Although tumor tissue biopsy sampling is the gold standard approach for diagnosis and for determining molecular pathways involved in the development of resistance to targeted therapies, the technique poses major challenges: difficulties in obtaining sufficient tumor cells for analysis, the need for invasive serial sampling to monitor response, and the potential for selection bias due to intratumoral and inter-tumoral heterogeneity. [6] [7] [8] Such challenges highlight the need for more effective biopsy methods. "Liquid biopsy" analysis using circulating tumor cells (CTCs) or plasma-derived circulating tumor DNA (ctDNA) offers a non-invasive alternative to tissue biopsies. CTCs were identified in 1869, by Thomas Ashworth, and correspond to one of the stages of the metastatic dissemination process. They occur at very low levels in blood (1 in 10 6 -10 7 nucleated blood cells), presenting a challenge for detection. 9 Currently, the most commonly used detection system is CellSearch TM (Veridex, Raritan, NJ, USA), which allows quantification of CTCs and also the isolation of viable CTCs, from which genetic material can potentially be extracted, amplified, and analyzed.
In this review, we focus on the potential clinical applications of liquid biopsy using ctDNA in colorectal cancer (CRC). Despite substantial survival gains over recent years, CRC remains a leading cause of death in developed countries, with over half of patients developing metastatic disease. 10, 11 CRC may be considered as a genetic disease characterized by molecular heterogeneity and sequential genetic alterations. 11, 12 As a consequence of better understanding of colorectal carcinogenesis, targeted agents have been developed which have improved outcomes in patients with metastatic CRC (mCRC). These include monoclonal antibodies (mAbs) targeting two major pathways critical to tumorigenesis, namely, the epidermal growth factor receptor (EGFR) and vascular endothelial growth factor (VEGF) signaling pathways. These mAbs led to a substantial increase in overall survival, which is over 30 months in recent studies. A strong emphasis on the clinical problem of primary and acquired resistance to anti-EGFR agents has heightened interest in the potential for liquid biopsy to predict and monitor resistance in CRC. 11 While recognizing the potential for CTCs to monitor tumor dynamics and provide insight into the characteristics of cells responsible for metastasis, 13 at present there are limited data supporting the use of CTCs in clinical practice over the short term. 11 Accordingly, studies on the use of ctDNA in diagnosis and screening, detection of recurrence, its prognostic value, monitoring tumor burden or response during treatment, and tracking resistance are reviewed.
Liquid biopsy using ctDNA in blood
The presence of circulating cell-free DNA (cfDNAs) in human blood was first described in 1948. 14 In 1977, cancer patients were found to have higher plasma cfDNA levels than healthy individuals. 15 Current molecular biology techniques make it easy to detect DNA in the blood, paving the way for major research advances and new clinical applications.
The fraction of cfDNA that carries tumor-specific alterations is termed ctDNA. 16 Tumor cells release ctDNA into the bloodstream by apoptosis and necrosis, and probably to a lesser extent, by active secretion. 16, 17 Apoptotic tumor cells are thought to be the most important sources of ctDNA in the blood, as detectable ctDNA is typically highly fragmented (between 180 and 200 base pairs), which is indicative of apoptotic DNA. 16, [18] [19] [20] It is not known if all clones in a multiclonal tumor with genetic instability will shed DNA into the circulation. Some clones may have more proliferative and less apoptotic activities than others. Indeed, the genetic profile detected using ctDNA probably mirrors clones with high apoptotic activity. In addition, detectable ctDNA levels in patients with cancer do not always correspond to the ability to detect CTCs, suggesting that these two biomarkers are distinct entities. 16, [18] [19] [20] [21] CTCs can potentially be assessed in all patients rather than a subset with a known gene mutation, but some patients may test positive for ctDNA and negative for CTCs due to the very low CTC counts or absence of CTC in blood. 22 Furthermore, CTC counts are lower in CRC compared with other cancers, probably because many CTCs released from a primary tumor in the colon become trapped in the liver before reaching the systemic circulation. 23 Consistent with these observations and using current techniques, the diagnostic performance of ctDNA is superior to that of CTCs in CRC.
Isolation of ctDNA from both plasma and serum cfDNA is possible due to the technical ability to detect genetic alterations at low levels in cfDNA. 19 These ctDNA fragments contain genetic defects identical to those seen in the original tumor, and virtually, all cancer-related molecular alterations can be detected, including somatic point mutations, translocations, and DNA methylation changes. [24] [25] [26] However, it is not currently possible to isolate ctDNA from other circulating DNAs or to confirm that cfDNA is tumor derived unless molecular alterations (genetic or epigenetic) are detected.
There are two main approaches for the detection of mutations in cfDNA. The first involves a targeted approach that includes the analysis of known genetic changes from a given tumor type in a small set of frequently occurring mutations (e.g. KRAS, NRAS, BRAF, and EGFR mutations in CRC). The second involves a non-targeted approach using total cfDNA quantification, which is less cost-effective. A non-targeted approach using genome-wide analysis of cfDNA or whole-exome sequencing is also possible. 27 Levels of ctDNA in blood can vary widely between patients due to differences in tumor DNA release mechanisms and the effectiveness of cfDNA clearance, with estimates of the proportion of ctDNA from total cfDNA varying from 0.01% to 90%. 20, 28 Serum cfDNA levels are significantly higher than plasma levels 20, [29] [30] [31] [32] [33] due to clotting of white blood cells in the collection tube, leading to their lysis. 20, 32, 33 Consequently, serum ctDNA is diluted by genomic DNA released from white blood cells, and plasma is preferred as a source of ctDNA. 19, 34 In cancer patients, cfDNA levels increase further in metastatic disease, suggesting that total cfDNA is related to tumor burden. 20 However, cfDNA elevation also occurs in inflammation (which is associated with accelerated shedding of DNA into the bloodstream) and conditions involving organ necrosis (e.g. myocardial infarction), whereas ctDNA is specific to one or more cancer subtypes. Nevertheless, lung cancer patients were found to have significantly higher plasma cfDNA levels than patients with chronic respiratory inflammation, suggesting that cfDNA elevation in cancer may be mainly due to tumor development rather than inflammation. 35 Extracellular vesicles (including exosomes, microvesicles, and apoptotic bodies) are another source of tumor DNA and can be secreted by cancer cells into the blood. Exosomes are spherical, nano-sized vesicles released by exocytosis from multi-vesicular bodies of the late endosome. 36, 37 They are exocytosed in a constitutive manner from both normal and tumor cells and are present in blood and other body fluids. Tumor-derived exosomes have pleiotropic roles affecting tumor growth and development. Exosomes contain proteins, lipids, and nucleic acids, including double-stranded DNA, single-stranded RNA, long non-coding RNA, and microRNA (miRNA). As a result, tumor mutations can be identified using exosomederived nucleic acids. Tumor DNA from extracellular vesicles is unlikely to contribute to detectable plasma ctDNA levels since exosomes contain mostly miRNA, with low levels of double-stranded DNA. In addition, DNA release from exosomes in the blood is poorly understood but probably low. 38, 39 The vesicles can be extracted from serum and may represent a promising future alternative to ctDNA for tumor DNA analysis, as tumor-derived genomic material from extracellular vesicles is more concentrated and better preserved. 36, 37 Some studies have also evaluated circulating free miRNA (non-exosomal) as biomarkers, but results are preliminary; neither circulating free miRNA nor exosomal miRNA are ready to be used as a liquid biopsy in clinical practice. 40 Levels of circulating DNA are influenced by clearance, degradation, and other physiological filtering events in blood and lymphatic circulation. [41] [42] [43] Nucleic acids are cleared from the blood by the liver and kidneys and have a variable half-life in circulation, ranging from 15 min to 2 h. 41 Defining the tumor genetic profile based on blood ctDNA levels of an individual patient has been made possible with the advent of increasingly sensitive techniques. [41] [42] [43] Early studies used Sanger sequencing to detect plasma ctDNA, but this technique has many shortcomings, including low sensitivity and laborious protocols. "Second-generation" sequencing techniques provide significantly higher sensitivity for ctDNA detection (Table 1 ). For example, the polymerase chain reaction (PCR)-based bidirectional pyrophosphorolysis-activated polymerization (Bi-PAP) technique can precisely detect a single-nucleotide change using a pyrophosphorolysis-activated oligonucleotide that is then extended by DNA polymerization. 44 As with most PCR-based techniques, it is very specific but has limited sensitivity for ctDNA detection. BEAMing (beads, emulsion, amplification, and magnetics) is a digital PCR technique in which the target DNA segment is amplified using primers containing known tag sequences and covalently bound to magnetic beads. 20 Following incubation with fluorescently labeled hybridization probes, magnetic flow cytometry is used to quantify beads containing the DNA mutation. Next-generation sequencing (NGS) is a broad term encompassing various high-throughput technologies with a reduced cost per assay. These include deep sequencing using a probe panel consisting of DNA oligonucleotides targeting frequently mutated regions in the gene of interest. 45, 46 Systemic PCR and sequencing errors may compromise the ability of high-throughput techniques to detect rare mutations. To address this limitation, the Safe-Sequencing System (Safe-SeqS) uses a unique DNA sequence or "barcode" to tag each DNA fragment that is to be amplified, followed by redundant sequencing of the amplified fragments. 45, 47 This approach allows confident identification of low-frequency mutations, but PCR sampling efficiency and sampling bias may be issues when using unique identifiers. 48 Development of "third-generation" whole-genome sequencing techniques is ongoing. These include personalized analysis of rearranged ends (PARE), a technique developed to detect unselected genetic events across the whole genome. 49 A more costeffective approach for mutation detection would be wholeexome sequencing, which may have potential for identifying mutations associated with acquired drug resistance and studying clonal evolution. 50 A new technique known as DREAMing (Discrimination of Rare EpiAlleles by Melt) enables analysis of very rare epiallelic variants in liquid biopsy samples. 51 Bettegowda et al. 22 demonstrated the ability to obtain valuable information on a tumor's genetic make-up from a blood sample. By directly comparing ctDNA in 187 tumors originating from 16 different tissue types, and evaluating which ctDNA measurements could prove clinically useful, the authors demonstrated that ctDNA levels varied among tumor types, with all patients with mCRC having detectable ctDNA, compared with under 10% of those with glioma. Investigating ctDNA could also help to account for molecular heterogeneity, because the peripheral blood is a pool of DNA derived from the primary tumor and different metastatic sites and may therefore provide a comprehensive real-time picture of the whole tumor burden in an individual patient. This approach has potential in several important clinical applications.
Potential clinical applications of liquid biopsy in colorectal cancer

Cancer diagnosis and screening
Common gene mutations in CRC include KRAS and BRAF V600E, with a frequency of approximately 40% and 5%-9%, respectively. [52] [53] [54] [55] Highly sensitive techniques can detect nearly all such mutations, but a good screening or diagnostic test should identify at least 80% of cases, thus ctDNA detection of individual mutations has insufficient sensitivity for population screening (≈50% if using KRAS and BRAF ctDNA testing). In a recent study, the overall sensitivity for detection of RAS mutations was 63%, but was 100% for patients whose primary tumor remained in place versus 46% in those who had undergone resection of the primary tumor. 56 Regarding KRAS-mutated tumors, sensitivity to detect KRAS-mutated ctDNA ranges from 20% to 60% for non-metastatic disease (with higher sensitivity in stage III than in stages I-II) to 80%-100% for metastatic disease. 57, 58 By comparison, the fecal immunochemical test (FIT) had a sensitivity of 79% (95% confidence interval (CI) = 69%-86%) and specificity of 94% (95% CI = 92%-95%) for CRC screening, based on data from 19 studies in asymptomatic, average-risk adults. 59 An alternative approach to identifying ctDNA is aberrant DNA methylation of specific promoter regions, which is more consistent between tumors than mutations. 60 DNA methylation is an early event in CRC carcinogenesis, and various studies have investigated the use of methylated ctDNA for CRC screening and diagnosis ( Table 2 ). [61] [62] [63] [64] [65] [66] [67] [68] [69] Several studies evaluated the pretreatment methylation status of the Septin 9 (SEPT9) gene promoter. SEPT9 methylation demonstrated a sensitivity of about 70% (50%-90%) and a specificity of about 90% (70%-100%) to detect CRC, depending on disease stage (metastatic vs non-metastatic). 43, 63, 64, [68] [69] [70] However, plasma SEPT9 methylation demonstrated disappointing results in a large prospective study of 7941 patients undergoing screening colonoscopy, with a standardized sensitivity of only 48% (35% for stage I, 63% for stage II, and 46% for stage III). 62 It is important to note that these findings are dependent on the sensitivity of the technique used. These techniques are complex and heterogeneous, with variation in both the segment of the SEPT9 gene analyzed and the cut-off level considered to be positive. These factors could account for the differing SEPT9 methylation sensitivity reported. A meta-analysis of three studies that directly compared methylated SEPT9 and fecal occult blood testing (FOBT) as a screening tool for CRC found that methylated SEPT9 had a pooled sensitivity of 76% (95% CI = 71%-80%), compared with 67% (95% CI = 60%-74%) for FOBT, leading to a better diagnostic efficiency for methylated SEPT9. 71 A methylation SEPT9 assay was recently approved in the United States for screening of CRC (Epi proColon ® ; Epigenomics, Inc., Germantown, MD, USA). In addition, in 2014, the US Food and Drug Administration approved Cologuard ® , the first stool-based colorectal screening test that detects the presence of red blood cells and DNA mutations that may indicate the presence of colon cancer or precursors to cancer. 72 Others trials evaluating multitarget stool DNA testing are also ongoing. Nevertheless, we believe that further data and standardization are necessary before these approaches can be used in clinical practice.
Regarding future directions, recent studies have identified additional DNA methylation biomarkers that may be relevant for CRC diagnosis. 51, 73, 74 Promising results have also been reported using multigene methylation signatures for CRC screening in order to increase sensitivity and specificity. [61] [62] [63] [64] [65] [66] [67] [68] [69] For example, an approach using a BCAT1 and IKZF1 methylation assay identified approximately 70% of CRC. [75] [76] [77] 
Detection of tumor recurrence, minimal residual disease, and prognosis value
Surgery alone cures a large fraction of patients with localized CRC. However, there are currently no effective means to identify which patients have residual disease that will result in recurrence. Consequently, patients with high-risk clinicopathological features indiscriminately receive potentially toxic and unnecessary adjuvant therapy. As ctDNA is a potential marker of residual disease after resection, liquid biopsy may help determine which patients will experience recurrence and would benefit most from adjuvant treatment. To date, few studies have evaluated ctDNA as a marker of recurrence after curative surgery in CRC. However, the available studies have found that ctDNA detection after surgical resection is associated with minimal residual disease and a high recurrence rate. 20, [78] [79] [80] [81] [82] Studies specifically evaluating the tumor recurrence rate after curative surgery are shown in Table 3 . 20, 79, 81, 82 Some studies have used KRAS-mutated ctDNA to detect CRC recurrence. 79 In one such study, 63% of patients with detectable KRAS-mutated ctDNA postoperatively developed recurrence, compared with only 2% of patients who remained serum mutant negative, giving a sensitivity to detect recurrence of 91% and specificity of 88%. 79 Detection of ctDNA during follow-up was an independent predictor of disease recurrence (hazard ratio (HR) = 6.37, 95% CI = 2.26-18.0; p < 0.001). Diehl et al. investigated the use of serial plasma ctDNA measurements to monitor recurrence and tumor burden dynamics over time in 18 patients with CRC and complete surgical resection. The specified ctDNA mutants (all tumors had mutations in one or more of the four genes assessed: APC, KRAS, TP53, and PIK3CA) were detectable at first follow-up (13-56 days after surgery) in 80% of cases, with recurrence occurring in 94% of this group. In marked contrast, no recurrence occurred in the 20% of patients with undetectable ctDNA. 20 A recent study using a personalized Safe-SeqS assay reported that detection of ctDNA after surgery for stage-II CRC identified a subset of patients at very high risk of recurrence if not treated with chemotherapy: radiologic recurrence was confirmed in 79% of patients who tested positive for ctDNA postoperatively, compared with 9.8% of those with negative ctDNA. 82 The sensitivity and specificity of post-operative ctDNA in predicting recurrence at 3 years were 48% and 100%, respectively. These findings indicate that ctDNA may help to detect minimal residual disease after resection, to predict tumor recurrence with high sensitivity and to determine which patients will most benefit from adjuvant treatment. In this setting, ctDNA should be measured before surgery and again before the initiation of adjuvant therapy (typically 6 weeks after surgery) to facilitate therapeutic decision-making. More sensitive techniques have a higher probability of detecting ctDNA and could account for the differences in sensitivity and specificity observed across studies using the same biomarkers.
Several small studies investigating ctDNA as a prognostic marker in localized CRC have shown that ctDNA detection before surgery is associated with locoregionally advanced (stage III) disease, a high risk of recurrence, and poor prognosis (Table 4) . 24, 67, 80, 81, [84] [85] [86] [87] [88] [89] In a cohort of 58 patients with primary CRC (stages I-IV), 39 patients with KRAS exon 2 mutations and/or p16 hypermethylation in the tumor underwent preoperative plasma screening. Among stage-I to stage-III patients, the 2-year recurrence-free survival rate differed according to whether ctDNA was detected in plasma (66%) or not (100%) (p = 0.044). 90 Similarly, the 2-year overall survival rate for patients with detectable ctDNA was 48%, compared to 100% for patients with no ctDNA (p < 0.03). Nevertheless, some studies have found no prognostic value for ctDNA detection before surgery. 24, 67, 80, 81, [84] [85] [86] [87] [88] [89] 91 For example, in a recent study, KRAS, TP53, and p16INK4A mutations were used to detect ctDNA in 66 patients with CRC. Detection of mutant KRAS in the blood before surgery predicted recurrence (p < 0.01), but not overall survival. 80 Large prospective trials are needed to confirm the prognosis value of ctDNA. Future studies evaluating post-operative ctDNA levels could generate personalized markers based on the unique mutational profile of resected tumors, offering exquisitely high specificity to predict recurrence and/or evaluate prognosis. Sensitivity will rely on the ability to detect low levels of ctDNA released from micrometastatic deposits not detectable by imaging or other diagnostic modalities. Prospective trials are needed to evaluate whether early detection of recurrence using ctDNA can improve survival compared with standard imaging and whether adjuvant chemotherapy can prevent recurrence in patients with high pre-and/or post-operative ctDNA levels. To conclude, detection of ctDNA after surgery is very useful and highly associated with disease recurrence, but requires tumors with a mutated gene that can be detected in cfDNA. In contrast, the prognostic value of ctDNA remains unclear.
Monitoring tumor burden or response during treatment
Measuring ctDNA may be useful in monitoring tumor burden, a central aspect of patient management that is currently assessed using imaging and serum protein biomarkers, such as carcino-embryonic antigen (CEA). As the ctDNA profile can be absolutely specific for each patient's individual tumor, 92 its use would avoid falsepositive and false-negative results when assessing response. Another benefit would be the real-time picture of tumor burden, taking into account that ctDNA has a half-life of less than 2 h, compared with commonly used protein biomarkers, which can take weeks to clear from the blood. 22 In the aforementioned work by Diehl et al., 20 ctDNA was detectable in all patients before surgery, and serial blood sampling revealed oscillations in the ctDNA level that correlated with the extent of surgical resection. In this cohort, ctDNA levels were a more reliable and sensitive indicator (100%) than CEA (56%). Serial ctDNA measurements were likewise used to monitor tumor burden in six consecutive patients undergoing adjuvant treatment for CRC (stages I-IIIB). 93 Tumor burden measured by variant allele frequencies and absolute ctDNA concentration decreased markedly after surgery and adjuvant chemotherapy, with a mean ctDNA concentration of 0.163 and 0.038 ng/mL before and after surgery, respectively. The only patient with disease recurrence had a 13-fold increase in ctDNA levels. Danish researchers used NGS and droplet digital PCR to identify patient-specific somatic structural variants, which were then used as personalized ctDNA assays to monitor the disease burden after CRC surgery. 94 Their technique enabled efficient temporal assessment of disease status, with detection of metastatic recurrence at a mean of 10 months earlier than conventional follow-up. The authors concluded that ctDNA analysis is an exquisitely specific and highly sensitive approach for monitoring disease load.
Liquid biopsy also has potential for monitoring the response to treatment ( Table 5 ). [95] [96] [97] An analysis of 31 mCRC patients demonstrated that ctDNA detection (KRAS mutation and RASSF2A methylation) was highly predictive of clinical outcome under chemotherapy. 95 Median progression-free survival (PFS) was 5 months in patients positive for ctDNA versus 14 months in patients negative for ctDNA (p = 0.004). Separately, Spindler et al. 96, 97 developed a sensitive PCR method to quantitatively assess cfDNA as well as KRASand BRAF-mutated ctDNA in plasma. Serial plasma samples were obtained from 108 heavily pretreated patients before and during treatment with cetuximab and irinotecan. Low baseline cfDNA levels (<25% quartile) were associated with a higher disease control rate. 97 Patients with KRAS-mutant ctDNA levels in the highest quartile (>75% quartile) had a disease control rate of 0%, compared with 42% in patients with levels below the 75% quartile (p = 0.048). Decreases in cfDNA of >50% at cycle 3 compared to baseline were associated with treatment response (40% vs 17% in those with a lesser decrease, p = 0.04). 96 Besides enabling the earlier detection of progression, another potential advantage of using ctDNA to assess treatment response is the ability to minimize cumulative exposure of patients to ionizing radiation associated with surveillance imaging during long-term follow-up. 98 Conversely, potential difficulties using ctDNA to monitor response may be envisaged in patients treated with drugs that induce apoptosis and tumor necrosis, thus increasing the shedding of ctDNA into circulation. As with other tumor markers, such as CEA, an initial increase in ctDNA is not necessarily associated with tumor progression; rather, it is the evolution over time that will be predictive of response (initial increase and then secondary decrease). Efficient ctDNA monitoring has the potential to become a practicechanging tool. Changes in ctDNA may predict for treatment response early in the course of therapy, thereby creating a critical window of opportunity for intervention (i.e. treatment modification). Nevertheless, no prospective trial has yet demonstrated that detection of earlier disease progression with ctDNA, compared with imaging, and more rapidly change treatment results in improved survival.
Tracking resistance and tailoring therapies
CRC patients with wild-type RAS disease who initially respond to anti-EGFR treatment will ultimately acquire secondary resistance after a few months. The molecular basis of acquired resistance is an active area of research. Mutations linked to acquisition of anti-EGFR resistance have been reported in the EGFR extracellular domain (S492R), KRAS, NRAS, BRAF, and PIK3CA genes, as well as two novel EGFR ectodomain mutations (R451C and K467T). 99 Amplification of KRAS and co-occurring amplifications, such as MET and ERBB2, are additional mechanisms of resistance to anti-EGFR therapies. [100] [101] [102] In this setting, serial analysis of ctDNA provides a valuable opportunity for early detection of molecular changes that potentially confer resistance, 47,103-105 thereby enabling early treatment modification, which may prevent disease progression.
A cornerstone of ctDNA analysis in CRC has been the identification of acquired RAS mutations associated with secondary resistance to anti-EGFR therapy. Misale et al. 106 analyzed metastatic tissue from patients who developed resistance to cetuximab or panitumumab, demonstrating the emergence of KRAS amplification in one tumor and acquisition of secondary KRAS mutations in six of 10 cases analyzed. The onset of secondary KRAS mutations was detected in serum ctDNA analysis as early as 10 months before radiographic documentation of disease progression. A cohort of patients treated with chemotherapy alone was analyzed as a control group; no acquired KRAS mutations were found at disease progression in their serum samples.
Among patients who received third-line treatment with cetuximab and irinotecan, Spindler et al. 96 identified a discrepancy in mutational status between the primary tumor, baseline plasma samples, and/or plasma status at the time of progression in 19% of patients. In all, 12 patients had primary KRAS-mutant tumors but the mutation was not detected in the baseline plasma analysis, 2 patients had primary mutant disease and different types of mutations detected later in the plasma, and interestingly, 5 patients acquired new KRAS or BRAF mutations at progression. 96 In another study, Diaz et al. 107, 108 found that KRAS mutations in serum were present during panitumumab treatment in 38% of patients which have initially WT tumors, which were detected on average 5 months before radiological progression. Recently, blood samples from mCRC patients included in the CORRECT trial were reanalyzed using BEAMing analysis. KRAS-mutated ctDNA was identified in 48% of patients who had received anti-EGFR therapy and whose archival tumor tissue DNA was KRAS wild type. 109 Bettegowda et al. 22 designed a multiplexed, sequencingbased assay to query known mutated hotspots of several genes in the EGFR pathway that were not present in the primary tumor of patients receiving panitumumab monotherapy. They evaluated 24 mCRC patients' progressing after achieving an objective response to anti-EGFR treatment; of these, 23 (96%) had up to 70 novel plasma mutations in genes involved in the mitogen-activated protein kinase pathway. Moreover, this assay predicted treatment resistance before radiologic progression occurred. Bardelli et al. 100 also demonstrated amplification of the MET locus in ctDNA before radiographic progression.
We can deduce some peculiar features of mutations arising under anti-EGFR pressure which are detectable in blood by ctDNA analysis. First, CRC tumors that acquire resistance to anti-EGFR therapy do not show the emergence of a single mutated clone, but typically the concomitant presence of diverse genetic abnormalities. 102 It is not yet known whether these molecular changes are exclusively due to a passive clonal selection mechanism or involve treatment-induced mutagenesis. Second, there is a marked overlap between molecular abnormalities associated with primary resistance (i.e. RAS and BRAF mutations) and those detected by liquid biopsy eventually leading to secondary resistance. One exception is the EGFR mutation, which has only been described in secondary resistance. 110 Nevertheless, the prevalence of KRAS or NRAS codon 61 mutations is higher in acquired resistance compared to untreated mCRC. 22, 106 In conclusion, early detection of resistance to EGFRtargeted agents by liquid biopsy may help clinicians in deciding when to stop drugs and identifying driving mutations underlying resistance that can be targeted. 99 However, no prospective trial has yet demonstrated improved survival through earlier detection of mutations that confer anti-EGFR resistance with ctDNA, as compared with standard imaging. In addition, therapeutic options remain limited for patients with tumoral RAS pathway mutations. Plasma DNA can also indicate possible rechallenge strategies, that is, disappearance of RAS-mutated ctDNA. Anti-EGFR rechallenge has not yet been studied in a prospective trial.
Discussion
Analysis of ctDNA is a promising technology with the potential to improve the representation of all tumor lesions and the assessment of cancer heterogeneity, without the invasiveness of current biopsy methods. Studies suggest that liquid biopsy may detect minimal residual disease and tumor recurrence after curative surgery with greater sensitivity and specificity than current imaging and serum tumor markers. Liquid biopsies are also expected to be useful in establishing a more accurate prognosis and to greatly facilitate ongoing monitoring. The most attractive benefit of liquid biopsies is the ability to obtain a dynamic, ongoing real-time picture of the tumor genomic landscape in a given patient, providing the opportunity to tailor therapies throughout the disease course, from diagnosis to the development of resistance.
Many questions remain. Despite the proliferation of ctDNA publications, most involve very small patient numbers and none provide definitive evidence to guide the clinical application of ctDNA analysis (e.g. we do not know the relevance of changing anti-EGFR treatment when KRAS mutation appears in the blood versus at the time of radiological progression). Large prospective trials are needed to address clinically relevant questions, with a focus on using ctDNA to detect minimal residual disease and to monitor the emergence of molecular resistance in order to allow early adaptation of further treatment lines, as well as on measuring the impact of ctDNA analysis on disease-free, progression-free, and overall survivals.
It is essential to standardize the techniques used to analyze ctDNA in future trials, as results are dependent on the sensitivity of the technique used, with more sensitive sequencing techniques having a higher probability of detecting minority subclones. As in the tumor, the clinical relevance of minority subclones detected in the blood is unknown (e.g. the potential impact on resistance to anti-EGFR therapy). Previous studies suggested that patients with mCRC tumors containing no more than 1%-2% of KRAS-mutated subclones may benefit from anti-EGFR therapies. 111, 112 However, no cut-off level for KRASmutated ctDNA that predicts resistance to anti-EGFR therapies has yet been established, thus, it is not known, for example, whether detection of 1% of cfDNA harboring a RAS mutation in a clinically responding wild-type RAS tumor should prompt a change in treatment.
Further contributing to uncertainty over when ctDNA findings support a change in the treatment strategy, it is not known whether some genomic alterations detected using ctDNA drive tumor progression or are merely "passenger" mutations. Targeting these alterations with new drugs may be not relevant if there are not driver mutations. It remains unclear exactly what the mutation profile of ctDNA reflects; it could reflect the profile of cells that are already dead, rather than those that are going to cause tumor progression. The extent to which ctDNA accurately reflects the heterogeneity of all tumor lesions is also unknown. Additional research is needed to elucidate why ctDNA levels vary among cancer patients, such as determining whether this variability is due to tumor biology and/or other parameters such as DNA clearance from plasma. Greater knowledge of the dynamics of ctDNA release is necessary before designing prospective clinical trials-for example, to understand the best timing for ctDNA assessment relative to therapy.
Exosomes are of great interest as an alternative source of circulating nucleic acids for liquid biopsy. Several studies have demonstrated that miRNA from circulating exosomes are similar to those of the originating cancer cells, suggesting a role for exosomal miRNA as potential biomarkers. 113 Detection of exosomal miRNA may therefore offer a new diagnostic approach in CRC, as plasma miRNAs are promising markers for early detection of CRC tumors 114 and can also predict CRC recurrence. 115 Studies comparing ctDNA, free circulating miRNA, and exosomal miRNA are necessary to evaluate the performance of each marker.
When a promising new technology emerges, we tend to forget about existing technologies, including those that are currently under development. CTC analysis has a sensitivity of about 80% to detect CRC, while CTC levels correlate with both tumor stage [116] [117] [118] and recurrence after curative surgery. 119 CTCs are also associated with treatment response and prognosis in mCRC. 120 However, in this indication, CTC data are less robust than those for ctDNA. To our knowledge, there have been no studies to date comparing CTCs and ctDNA in CRC. Of note, a study in multiple tumor types found no cases in which CTCs were detected and ctDNA was absent, whereas in 81% of cases in which ctDNA was detected, no CTCs were detectable. 22 Demonstrating reproducibility of results comparing ctDNA and CTCs is a key challenge, and both techniques require standardized protocols and validation in large trials. Comparative studies are needed to establish the relative sensitivity of each technique and to determine whether combining both techniques is advantageous. It is likely that ctDNA will be superior to CTCs for diagnosis and detecting recurrence. Conversely, CTCs have advantages for analyzing treatment response and choosing targeted therapy since they are viable cells and can undergo additional testing, such as characterization of the current tumor phenotype using immunocytochemistry or fluorescence in situ hybridization (FISH). CTCs can also provide insight into tumor heterogeneity, and in breast cancer, CTCs were recently found to have dynamic interconverting phenotypes influenced by chemotherapy. 121 Orthotopic CTC-derived tumor models allow the elucidation of signaling pathways involved in tumor progression and drug resistance.
Extensive data now support the potential of liquid biopsy as a novel technology with potential for optimizing CRC assessment, monitoring evolution, tracking resistance to targeted therapies, and designing tailored treatments. There is great interest in both ctDNA and CTCs, which may provide complementary information. Large, well-designed trials using standardized methodology are needed to compare the performance of ctDNA with CTCs and, in future, extracellular vesicles, in order to optimize the clinical application of each technique and complete the transition of blood-based assays from bench to bedside.
